The FDA’s reintroduction of advisory committees is stirring mixed reactions among analysts, with some viewing it as a positive shift for the biopharma sector while others await more substantial regulatory reforms. AbbVie has raised its 2026 outlook, buoyed by growth in immunology and neurology, and is eyeing potential M&A opportunities. Meanwhile, Biogen’s growth trajectory remains stagnant, though a recent acquisition and a robust late-stage pipeline may provide some relief for the company.
Regeneron reported $3.6 billion in Q1 2026, despite a slight miss with its Eylea HD treatment, as attention turns to key upcoming clinical readouts. Eli Lilly continues its aggressive acquisition strategy, recently securing a $7 billion deal for Kelonia Therapeutics, further positioning itself in the gene delivery space. The competitive landscape is heating up, particularly in the Alzheimer’s market, where dosing differences between Eli Lilly’s Kisunla and Biogen’s Leqembi are set to come into focus.
For market professionals, the ongoing M&A activity and evolving FDA landscape highlight critical shifts in biopharma strategies, suggesting that companies with strong pipelines and innovative therapies may gain significant competitive advantages in the coming years.
Source: biospace.com